The anticancer potential of thrombospondin-1 by inhibiting angiogenesis and stroma reaction during cervical carcinogenesis

Ming Ping Wu, Li-Wha Wu, Cheng-Yang Chou

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Tumor growth is angiogenesis dependent. Angiogenic switch (the acquisition of an angiogenic phenotype) is essential for cervical carcinogenesis. Thrombospondin-1 (TSP-1) is an endogenous angiogenic inhibitor with multiple functional domains and interacting receptors. The disruption of TSP-1 fence (the expression in basal epithelia) occurred concordantly during the transition from low-grade squamous intraepithelial lesion into high-grade squamous intraepithelial lesion. This concordance suggests that TSP-1 plays a role in the regulation of angiogenic switch during cervical carcinogenesis. Tumor vasculature as a therapeutic target offers a paradigm shift for anticancer therapy. Endothelial cells do not appear to acquire resistance during antiangiogenic therapy. Low-and-frequent dose "metronic" chemotherapy is found to be antiangiogenic, which is more effective in targeting tumor endothelia than traditional large, single bolus doses. Meanwhile, the invasion process of cancers is associated with stroma reaction, which is characterized by fibroblasts' activation. In addition to the well-known angiogenesis inhibitor, TSP-1 also has a novel role of blocking activated fibroblasts (myofibroblasts) from invading cancer. Activated fibroblasts during stroma reaction could be used as an efficient drug delivery system to prevent or slow the local growth of cancer cells. Elucidation of the mechanism by which fibroblasts are recruited into cancer stroma could lead to new insights into not only the mechanisms of cancer progression but also strategies for cancer treatment. A better understanding of stromal contributions to cancer progression will likely result in the identification of new therapeutics targeting the stroma.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalGynecology and Minimally Invasive Therapy
Volume5
Issue number2
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Thrombospondin 1
Carcinogenesis
Neoplasms
Fibroblasts
Angiogenesis Inhibitors
Therapeutics
Myofibroblasts
Drug Delivery Systems
Growth
Endothelium
Epithelium
Endothelial Cells

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Cite this

@article{6bf7b7a45f0b4ea7afff45d3b510dfc2,
title = "The anticancer potential of thrombospondin-1 by inhibiting angiogenesis and stroma reaction during cervical carcinogenesis",
abstract = "Tumor growth is angiogenesis dependent. Angiogenic switch (the acquisition of an angiogenic phenotype) is essential for cervical carcinogenesis. Thrombospondin-1 (TSP-1) is an endogenous angiogenic inhibitor with multiple functional domains and interacting receptors. The disruption of TSP-1 fence (the expression in basal epithelia) occurred concordantly during the transition from low-grade squamous intraepithelial lesion into high-grade squamous intraepithelial lesion. This concordance suggests that TSP-1 plays a role in the regulation of angiogenic switch during cervical carcinogenesis. Tumor vasculature as a therapeutic target offers a paradigm shift for anticancer therapy. Endothelial cells do not appear to acquire resistance during antiangiogenic therapy. Low-and-frequent dose {"}metronic{"} chemotherapy is found to be antiangiogenic, which is more effective in targeting tumor endothelia than traditional large, single bolus doses. Meanwhile, the invasion process of cancers is associated with stroma reaction, which is characterized by fibroblasts' activation. In addition to the well-known angiogenesis inhibitor, TSP-1 also has a novel role of blocking activated fibroblasts (myofibroblasts) from invading cancer. Activated fibroblasts during stroma reaction could be used as an efficient drug delivery system to prevent or slow the local growth of cancer cells. Elucidation of the mechanism by which fibroblasts are recruited into cancer stroma could lead to new insights into not only the mechanisms of cancer progression but also strategies for cancer treatment. A better understanding of stromal contributions to cancer progression will likely result in the identification of new therapeutics targeting the stroma.",
author = "Wu, {Ming Ping} and Li-Wha Wu and Cheng-Yang Chou",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.gmit.2015.09.001",
language = "English",
volume = "5",
pages = "48--53",
journal = "Gynecology and Minimally Invasive Therapy",
issn = "2213-3070",
publisher = "Elsevier Taiwan LLC",
number = "2",

}

TY - JOUR

T1 - The anticancer potential of thrombospondin-1 by inhibiting angiogenesis and stroma reaction during cervical carcinogenesis

AU - Wu, Ming Ping

AU - Wu, Li-Wha

AU - Chou, Cheng-Yang

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Tumor growth is angiogenesis dependent. Angiogenic switch (the acquisition of an angiogenic phenotype) is essential for cervical carcinogenesis. Thrombospondin-1 (TSP-1) is an endogenous angiogenic inhibitor with multiple functional domains and interacting receptors. The disruption of TSP-1 fence (the expression in basal epithelia) occurred concordantly during the transition from low-grade squamous intraepithelial lesion into high-grade squamous intraepithelial lesion. This concordance suggests that TSP-1 plays a role in the regulation of angiogenic switch during cervical carcinogenesis. Tumor vasculature as a therapeutic target offers a paradigm shift for anticancer therapy. Endothelial cells do not appear to acquire resistance during antiangiogenic therapy. Low-and-frequent dose "metronic" chemotherapy is found to be antiangiogenic, which is more effective in targeting tumor endothelia than traditional large, single bolus doses. Meanwhile, the invasion process of cancers is associated with stroma reaction, which is characterized by fibroblasts' activation. In addition to the well-known angiogenesis inhibitor, TSP-1 also has a novel role of blocking activated fibroblasts (myofibroblasts) from invading cancer. Activated fibroblasts during stroma reaction could be used as an efficient drug delivery system to prevent or slow the local growth of cancer cells. Elucidation of the mechanism by which fibroblasts are recruited into cancer stroma could lead to new insights into not only the mechanisms of cancer progression but also strategies for cancer treatment. A better understanding of stromal contributions to cancer progression will likely result in the identification of new therapeutics targeting the stroma.

AB - Tumor growth is angiogenesis dependent. Angiogenic switch (the acquisition of an angiogenic phenotype) is essential for cervical carcinogenesis. Thrombospondin-1 (TSP-1) is an endogenous angiogenic inhibitor with multiple functional domains and interacting receptors. The disruption of TSP-1 fence (the expression in basal epithelia) occurred concordantly during the transition from low-grade squamous intraepithelial lesion into high-grade squamous intraepithelial lesion. This concordance suggests that TSP-1 plays a role in the regulation of angiogenic switch during cervical carcinogenesis. Tumor vasculature as a therapeutic target offers a paradigm shift for anticancer therapy. Endothelial cells do not appear to acquire resistance during antiangiogenic therapy. Low-and-frequent dose "metronic" chemotherapy is found to be antiangiogenic, which is more effective in targeting tumor endothelia than traditional large, single bolus doses. Meanwhile, the invasion process of cancers is associated with stroma reaction, which is characterized by fibroblasts' activation. In addition to the well-known angiogenesis inhibitor, TSP-1 also has a novel role of blocking activated fibroblasts (myofibroblasts) from invading cancer. Activated fibroblasts during stroma reaction could be used as an efficient drug delivery system to prevent or slow the local growth of cancer cells. Elucidation of the mechanism by which fibroblasts are recruited into cancer stroma could lead to new insights into not only the mechanisms of cancer progression but also strategies for cancer treatment. A better understanding of stromal contributions to cancer progression will likely result in the identification of new therapeutics targeting the stroma.

UR - http://www.scopus.com/inward/record.url?scp=84981172875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981172875&partnerID=8YFLogxK

U2 - 10.1016/j.gmit.2015.09.001

DO - 10.1016/j.gmit.2015.09.001

M3 - Review article

VL - 5

SP - 48

EP - 53

JO - Gynecology and Minimally Invasive Therapy

JF - Gynecology and Minimally Invasive Therapy

SN - 2213-3070

IS - 2

ER -